Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting stents (DES). However, these studies included lesions smaller than recommended for these scaffolds and a suboptimal implantation technique. The ABSORB IV study, presented by Dr. Stone at TCT 2018 and published simultaneously in The Lancet, randomized patients to polymeric everolimus-eluting scaffold Absorb…
Chronic total occlusions: Pilot experience with BVS
Original Title: Percutaneous coronary intervention for chronic total occlusion of the coronary artery with implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. Reference: Maciej Lesiak, et al EuroIntervention 2016;12:e144-e151 Courtesy of Dr. Carlos Fava. Chronic total occlusion (CTO) is a real challenge and have a success rate of around 80% with trained…